Editorial
Split Viewer
Blood Res 2014; 49(1):
Published online March 31, 2014
https://doi.org/10.5045/br.2014.49.1.1
© The Korean Society of Hematology
Mantle cell lymphoma: a model for risk-adapted treatment approach
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Ghielmini, M, Zucca, E. How I treat mantle cell lymphoma. Blood, 2009;114;1469-1476.
- Rosenwald, A, Wright, G, Wiestner, A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 2003;3;185-197.
- Kang, BW, Sohn, SK, Moon, JH, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the Consortium for Improving Survival of Lymphoma. Blood Res, 2014;49;15-21.
- Ko, YH, Kim, CW, Park, CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer, 1998;83;806-812.
- Vose, JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol, 2013;88;1082-1088.
- Tiemann, M, Schrader, C, Klapper, W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol, 2005;131;29-38.
- Hoster, E, Dreyling, M, Klapper, W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 2008;111;558-565.
- Rummel, MJ, Niederle, N, Maschmeyer, G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 2013;381;1203-1210.
- Wang, ML, Rule, S, Martin, P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med, 2013;369;507-516.
- Brett, LK, Williams, ME. Current and emerging therapies in mantle cell lymphoma. Curr Treat Options Oncol, 2013;14;198-211.
PDF
Standard view
Export citation
Share Article
Editorial
Blood Res 2014; 49(1): 1-2
Published online March 31, 2014 https://doi.org/10.5045/br.2014.49.1.1
Copyright © The Korean Society of Hematology.
Mantle cell lymphoma: a model for risk-adapted treatment approach
Seok Jin Kim, M.D. Ph.D.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Ghielmini, M, Zucca, E. How I treat mantle cell lymphoma. Blood, 2009;114;1469-1476.
- Rosenwald, A, Wright, G, Wiestner, A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 2003;3;185-197.
- Kang, BW, Sohn, SK, Moon, JH, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the Consortium for Improving Survival of Lymphoma. Blood Res, 2014;49;15-21.
- Ko, YH, Kim, CW, Park, CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer, 1998;83;806-812.
- Vose, JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol, 2013;88;1082-1088.
- Tiemann, M, Schrader, C, Klapper, W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol, 2005;131;29-38.
- Hoster, E, Dreyling, M, Klapper, W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 2008;111;558-565.
- Rummel, MJ, Niederle, N, Maschmeyer, G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 2013;381;1203-1210.
- Wang, ML, Rule, S, Martin, P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med, 2013;369;507-516.
- Brett, LK, Williams, ME. Current and emerging therapies in mantle cell lymphoma. Curr Treat Options Oncol, 2013;14;198-211.
Previous Article
